233 related articles for article (PubMed ID: 33660221)
21. Risk of Severe Coronavirus Disease 2019 Disease in Individuals With Down Syndrome: A Matched Cohort Study From a Large, Integrated Health Care System.
Ku JH; Levin MJ; Luo Y; Florea A; Lin IC; Tian Y; Tseng HF
J Infect Dis; 2022 Sep; 226(5):757-765. PubMed ID: 35749312
[TBL] [Abstract][Full Text] [Related]
22. Balancing the Risks and Benefits of COVID-19 Vaccination for Pregnant Women and Their Children.
Yang C; Zhao H; Tebbutt SJ
Front Immunol; 2021; 12():748456. PubMed ID: 34975839
[No Abstract] [Full Text] [Related]
23. COVID-19 and Alzheimer's disease: how one crisis worsens the other.
Xia X; Wang Y; Zheng J
Transl Neurodegener; 2021 Apr; 10(1):15. PubMed ID: 33941272
[TBL] [Abstract][Full Text] [Related]
24. NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.
Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Pérez Potti A; Rivera Ballesteros O; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Söderdahl G; Österborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Loré K; Sobkowiak MJ; Gabarrini G; Healy K; Sällberg Chen M; Alici E; Björkström NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren HG
Mol Med; 2022 Feb; 28(1):20. PubMed ID: 35135470
[TBL] [Abstract][Full Text] [Related]
25. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
Cevik M; Grubaugh ND; Iwasaki A; Openshaw P
Cell; 2021 Sep; 184(20):5077-5081. PubMed ID: 34534444
[TBL] [Abstract][Full Text] [Related]
27. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
[TBL] [Abstract][Full Text] [Related]
28. Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event.
Fan BE; Shen JY; Lim XR; Tu TM; Chang CCR; Khin HSW; Koh JS; Rao JP; Lau SL; Tan GB; Chia YW; Tay KY; Hameed S; Umapathi T; Ong KH; Prasad BMRV
Am J Hematol; 2021 Sep; 96(9):E357-E361. PubMed ID: 34133027
[No Abstract] [Full Text] [Related]
29. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
[TBL] [Abstract][Full Text] [Related]
30. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19.
Corchado-Garcia J; Zemmour D; Hughes T; Bandi H; Cristea-Platon T; Lenehan P; Pawlowski C; Bade S; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Wagner T; Soundararajan V
JAMA Netw Open; 2021 Nov; 4(11):e2132540. PubMed ID: 34726743
[TBL] [Abstract][Full Text] [Related]
32. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis.
Li X; Raventós B; Roel E; Pistillo A; Martinez-Hernandez E; Delmestri A; Reyes C; Strauss V; Prieto-Alhambra D; Burn E; Duarte-Salles T
BMJ; 2022 Mar; 376():e068373. PubMed ID: 35296468
[TBL] [Abstract][Full Text] [Related]
33. Effects of adjusting public health, travel, and social measures during the roll-out of COVID-19 vaccination: a modelling study.
Leung K; Wu JT; Leung GM
Lancet Public Health; 2021 Sep; 6(9):e674-e682. PubMed ID: 34388389
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
Thompson MG; Stenehjem E; Grannis S; Ball SW; Naleway AL; Ong TC; DeSilva MB; Natarajan K; Bozio CH; Lewis N; Dascomb K; Dixon BE; Birch RJ; Irving SA; Rao S; Kharbanda E; Han J; Reynolds S; Goddard K; Grisel N; Fadel WF; Levy ME; Ferdinands J; Fireman B; Arndorfer J; Valvi NR; Rowley EA; Patel P; Zerbo O; Griggs EP; Porter RM; Demarco M; Blanton L; Steffens A; Zhuang Y; Olson N; Barron M; Shifflett P; Schrag SJ; Verani JR; Fry A; Gaglani M; Azziz-Baumgartner E; Klein NP
N Engl J Med; 2021 Oct; 385(15):1355-1371. PubMed ID: 34496194
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.
Hyams C; Marlow R; Maseko Z; King J; Ward L; Fox K; Heath R; Tuner A; Friedrich Z; Morrison L; Ruffino G; Antico R; Adegbite D; Szasz-Benczur Z; Garcia Gonzalez M; Oliver J; Danon L; Finn A
Lancet Infect Dis; 2021 Nov; 21(11):1539-1548. PubMed ID: 34174190
[TBL] [Abstract][Full Text] [Related]
36. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status.
Neidleman J; Luo X; McGregor M; Xie G; Murray V; Greene WC; Lee SA; Roan NR
Elife; 2021 Oct; 10():. PubMed ID: 34636722
[TBL] [Abstract][Full Text] [Related]
37. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
38. The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation.
Sandmann FG; Davies NG; Vassall A; Edmunds WJ; Jit M;
Lancet Infect Dis; 2021 Jul; 21(7):962-974. PubMed ID: 33743846
[TBL] [Abstract][Full Text] [Related]
39. Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects.
Bicher M; Rippinger C; Schneckenreither G; Weibrecht N; Urach C; Zechmeister M; Brunmeir D; Huf W; Popper N
Sci Rep; 2022 Feb; 12(1):2872. PubMed ID: 35190590
[TBL] [Abstract][Full Text] [Related]
40. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
